Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1

Abstract

We have previously shown that the breast cancer susceptibility gene, BRCA1, can transcriptionally activate the p27Kip1 promoter. The BRCA1-responsive element was defined as a 35 bp region from position −545 to −511. We next determined that within this region is also a potential binding site for the transcription factor Forkhead box (FOX)A1. RNA and protein analysis as well as immunohistochemistry showed that expression of FOXA1 correlated with the expression of the estrogen receptor in a panel of breast cancer cell lines and tissues. In transient transfection reporter assays, FOXA1 could activate the p27Kip1 promoter. Cotransfection of BRCA1 and FOXA1 resulted in a synergistic activation of the p27Kip1 promoter. Mutation of the FOXA1 DNA-binding site in the p27Kip1 promoter-luciferase construct significantly diminished the activity of FOXA1 alone or in combination with BRCA1. Cotransfection of FOXA1 and BRCA1 resulted in a greater amount of each protein compared to transfection of each expression vector alone. The half-life of FOXA1 was increased when coexpressed with BRCA1. Electrophoretic mobility shift assay analysis demonstrated that FOXA1 could bind to a wild-type oligonucleotide containing the FOXA1 binding site in the p27Kip1 promoter, but this binding was lost upon mutation of this FOXA1 binding site. The protein–DNA binding complex could be supershifted with an antibody directed against FOXA1. The activity of the p27Kip1 promoter as well as FOXA1 expression was reduced in cells treated with BRCA1 siRNA, thus silencing the expression of BRCA1 protein. In summary, we identified a FOXA1 binding site within the BRCA1-responsive element of the p27Kip1 promoter and showed that FOXA1 activated the promoter alone and in conjunction with BRCA1. Furthermore, we identified high expression of FOXA1 in breast cancer cell lines and tissues, discovered a role for BRCA1 in the regulation of p27Kip1 transcription and a possible interaction with BRCA1.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  • Brodie SG, Xu X, Qiao W, Li W-M, Cao L, Deng C-X . (2001). Oncogene 20: 7514–7523.

  • Cable PL, Wilson CA, Calzone FJ, Rauscher III FJ, Scully R, Livingston DM et al. (2003). Mol Carcinogen 38: 85–96.

  • Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA . (2003). Science 301: 215–218.

  • Catzevalos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C et al. (1997). Nat Med 3: 227–230.

  • Ciaparrone M, Yamamoto H, Yao Y, Sgambato A, Cattoretti G, Tomita N et al. (1998). Cancer Res 58: 114–122.

  • Cirillo LA, Lin FR, Cuesta I, Friedman D, Jarnik M, Zaret KS . (2002). Mol Cell 9: 279–289.

  • Cirillo LA, McPherson CE, Bossard P, Stevens K, Cherian S, Shim EY et al. (1998). EMBO J 17: 244–254.

  • Clark KL, Halay ED, Lai E, Burley SK . (1993). Nature 364: 412–420.

  • Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard SS et al. (1998). J Natl Cancer Inst 90: 1284–1291.

  • Costa RH, Kalinichenko VV, Lim L . (2001). Cell Mol Physiol 280: L823–L838.

  • Crowe AJ, Sang L, Li KK, Lee KC, Spear BT, Barton MC . (1999). J Biol Chem 274: 25113–25120.

  • Cunningham MA, Zhu Q, Hammond JM . (2004). Mol Endocrinol 18: 1756–1767.

  • Deans AJ, Simpson KJ, Trivett MK, Brown MA, McArthur GA . (2004). Oncogene 23: 6136–6145.

  • Fan S, Yuan R-q, Ma YX, Meng Q, Goldberg ID, Rosen EM . (2001). Oncogene 20: 8215–8235.

  • Ganesan S, Silver DP, Greenberg RA, Avni D, Drapkin R, Miron A et al. (2002). Cell 111: 393–405.

  • Houvras Y, Benezra M, Zhang H, Manfredi JJ, Weber BL, Licht JD . (2000). J Biol Chem 275: 36230–36237.

  • Jackson DA, Rowader KE, Stevens K, Jiang C, Milos P, Zaret KS . (1993). Mol Cell Biol 13: 2401–2410.

  • Jin GS, Kondo E, Miyake T, Shibata M, Takashima T, Liu YX et al. (2004). Acta Med Okayama 58: 197–205.

  • Kaestner KH, Katz J, Liu Y, Drucker DJ, Schutz G . (1999). Genes Dev 13: 495–504.

  • Kaestner KH, Knochel W, Martinez DE . (2000). Genes Dev 14: 142–146.

  • Kaufmann E, Knochel W . (1996). Mech Dev 57: 3–20.

  • Lai E, Prezioso VR, Tao WF, Chen WS, Darnell Jr JE . (1991). Genes Dev 5: 416–427.

  • Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J et al. (1999). Cancer Res 59: 3790–3794.

  • Medema RH, Kops GJ, Bos JL, Burgering BM . (2000). Nature 404: 782–787.

  • Ouchi T, Lee SW, Ouchi M, Aaronson SA, Horvath CM . (2000). Proc Natl Acad Sci USA 97: 5208–5213.

  • Ouchi T, Monteiro AN, August A, Aaronson SA, Hanafusa H . (1998). Proc Natl Acad Sci USA 95: 2302–2306.

  • Overdier DG, Porcella A, Costa RH . (1994). Mol Cell Biol 14: 2755–2766.

  • Robyr D, Gegonne A, Wolffe AP, Wahli W . (2000). J Biol Chem 275: 28291–28300.

  • Sasaki H, Hogan BL . (1993). Development 118: 47–59.

  • Shim EY, Woodcock C, Zaret KS . (1998). Genes Dev 12: 5–10.

  • Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Zhang H et al. (1997). Nature 389: 187–190.

  • van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M et al. (2002). Nature 415: 530–536.

  • Verbeek W, Gombart AF, Chumakov AM, Muller C, Friedman AD, Koeffler HP . (1999). Blood 93: 3327–3337.

  • Wang Q, Zhang H, Kajino K, Greene MI . (1998). Oncogene 17: 1939–1948.

  • Weinstein DC, Ruiz i Altaba A, Chen WS, Hoodless P, Prezioso VR, Jessell TM et al (1994). Cell 78: 575–588.

  • West M, Blanchette C, Dressman H, Huang E, Ishida S, Spang R et al. (2001). Proc Natl Acad Sci USA 98: 11462–11467.

  • Williamson EA, Dadmanesh F, Koeffler HP . (2002). Oncogene 21: 3199–3206.

  • Wolfrum C, Besser D, Luca E, Stoffel M . (2003). Proc Natl Acad Sci USA 100: 11624–11629.

  • Xia Y, Pao GM, Chen HW, Verma IM, Hunter T . (2003). J Biol Chem 278: 5255–5263.

  • Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R . (1998). J Biol Chem 273: 25388–25392.

  • Zaret K . (1999). Dev Biol 209: 1–10.

  • Zhang H, Somasundaram K, Peng Y, Tian H, Zhang H, Bi D et al. (1998). Oncogene 16: 1713–1721.

Download references

Acknowledgements

We thank B Weber, J Holt, J Wyke, T Sakai and K Zaret for the BRCA1 and FOXA1 expression vectors, and the p27Kip1 promoter constructs. We thank Normee Darwesh for excellent technical assistance and Indu B Seghal, MD, for the immunohistochemical analysis. We thank Marsha Diamond for a generous donation for this study as well as the Cindy and Alan Horn Trust, the Parker Hughes Foundation and NIH Grants. HP Koeffler holds the endowed Mark Goodsen Chair of Oncology and is a member of the Jonsson Cancer Center and the Molecular Biology Institute of UCLA. This work was supported by a Postdoctoral Fellowship for EA Williamson from the California Breast Cancer Research Program (6FB-0041) and to James O'Kelly from the Department of Defense (DAMD 17-02-1-0337).

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to E A Williamson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Williamson, E., Wolf, I., O'Kelly, J. et al. BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1. Oncogene 25, 1391–1399 (2006). https://doi.org/10.1038/sj.onc.1209170

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209170

Keywords

This article is cited by

Search

Quick links